⁹⁰Yttrium–ibritumomab tiuxetan: a novel treatment for non-Hodgkin’s lymphoma

Abstract

Indolent non-Hodgkin’s lymphomas (NHLs) comprise 35 – 40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. ⁹⁰Yttrium–ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67 – 80%, with a median remission duration of ~ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. ⁹⁰Yttrium–ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.

• 90Yttrium–ibritumomab tiuxetan
• monoclonal antibody
• non-Hodgkin’s lymphoma
• radioimmunoconjugate
• radioimmunotherapy